Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The beta-1 adrenergic receptor (β₁-AR), also known as ADRB1, is a member of the G protein-coupled receptor (GPCR) superfamily. It is primarily expressed in cardiac tissue but is also found in the kidney and adipose tissue. This receptor plays a central role in mediating the physiological effects of catecholamines—epinephrine and norepinephrine—on target organs, especially within the sympathetic nervous system. Activation increases heart rate, contractility, and renin release, and promotes lipolysis. Beta-blockers are drugs that antagonize BETA1 receptors and are widely used in treating hypertension, arrhythmias, and heart failure.
Beta-blockers antagonize BETA1 receptors, reducing heart rate and contractility by blocking sympathetic stimulation. Agonists like epinephrine and norepinephrine bind to BETA1, activating Gs protein, stimulating adenylyl cyclase, increasing cAMP production, and activating protein kinase A.
4 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Beta adrenergic receptor beta1 subtype (BETA1).